Skip to content

Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma

November 11, 2025 · 2 h 5 min

Show notes

Dave Ricks, the CEO of Eli Lilly, the world's most valuable pharmaceutical company, sits down with John and Patrick to discuss the complex business of drug development. Dave explains the true origin story of GLP-1s (from Gila monster saliva), why their potential goes far beyond weight loss to addiction and inflammation, and how "self-pay" has become the #1 way new patients get Zepbound. They cover the "shadow generic" industry undermining patents, the challenges associated with clinical trial enrollment, and what drove insulin list prices to $275 (while the net price was $40). This is a rare, candid look into the strategies, science, and future of pharma from one of the industry's most influential leaders.

Timestamps

(00:00) Introducing Dave Ricks

(05:07) Making R&D decisions

(10:10) Clinical trials

(24:59) Drug pricing

(32:43) Stimulating more R&D

(54:15) Pros and cons of US healthcare

(58:20) New pharma business models

(01:05:53) Stripe and enterprises

(01:07:00) China

(01:16:31) Generics

(01:22:37) GLP-1s

(1:37:43) r/Peptides

(01:41:25) LillyDirect

(01:46:35) Why do investors love LLY?

All episodes of Cheeky Pint

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.